Patient preferences in retinal drug delivery

Abstract Retinal vascular diseases (RVDs) are often treated with intravitreally (IVT) injected drugs, with relatively low patient compliance and potential risks. Ongoing research explores alternative RVD treatments, including eye drops and oral tablets. This study surveyed RVD patients treated with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Brandon Jacobs, Nicholas Palmer, Trupti Shetty, Helen Dimaras, Amir Hajrasouliha, Denis Jusufbegovic, Timothy W. Corson
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/eeb3a47168d044c68bc3bc7eb9108ec8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eeb3a47168d044c68bc3bc7eb9108ec8
record_format	dspace
spelling	oai:doaj.org-article:eeb3a47168d044c68bc3bc7eb9108ec82021-12-02T18:14:00ZPatient preferences in retinal drug delivery10.1038/s41598-021-98568-72045-2322https://doaj.org/article/eeb3a47168d044c68bc3bc7eb9108ec82021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-98568-7https://doaj.org/toc/2045-2322Abstract Retinal vascular diseases (RVDs) are often treated with intravitreally (IVT) injected drugs, with relatively low patient compliance and potential risks. Ongoing research explores alternative RVD treatments, including eye drops and oral tablets. This study surveyed RVD patients treated with IVT injections to establish factors influencing low compliance rates while gauging treatment delivery method preferences. Demographics, perspectives, and treatment preferences were collected via IRB-approved, self-administered survey sent to Glick Eye Institute patients treated via IVT injections. Demographics, diagnoses, and treatments were ascertained from respondents’ medical records. Gender, age, and number of IVT injections received were used as stratifications. Five-level Likert-style scales and t-tests evaluated responses and stratification comparisons. The most common diagnoses in the respondent population (n = 54; response rate = 5%) were age-related macular degeneration, macular edema, and diabetic retinopathy. Respondents had varying levels of education, income, and age. Most (83%) admitted feeling anxious prior to their first IVT injection, but 80% reported willingness to receive IVT injections indefinitely, with a preference for ophthalmologist visits every 1–3 months. Eye drops would be preferred over IVT injections by 76% of respondents, while 65% preferred oral tablets, due to several perceived negative factors of IVT injections and positive factors for eye drops. Stratified groups did not differ in responses to survey questions. RVD patients will accept IVT injections for vision preservation, but alternative delivery methods like eye drops or oral tablets would be preferred. Thus, development of eye drop and oral therapeutics for RVD treatment is further emphasized by these findings.Brandon JacobsNicholas PalmerTrupti ShettyHelen DimarasAmir HajrasoulihaDenis JusufbegovicTimothy W. CorsonNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Brandon Jacobs Nicholas Palmer Trupti Shetty Helen Dimaras Amir Hajrasouliha Denis Jusufbegovic Timothy W. Corson Patient preferences in retinal drug delivery
description	Abstract Retinal vascular diseases (RVDs) are often treated with intravitreally (IVT) injected drugs, with relatively low patient compliance and potential risks. Ongoing research explores alternative RVD treatments, including eye drops and oral tablets. This study surveyed RVD patients treated with IVT injections to establish factors influencing low compliance rates while gauging treatment delivery method preferences. Demographics, perspectives, and treatment preferences were collected via IRB-approved, self-administered survey sent to Glick Eye Institute patients treated via IVT injections. Demographics, diagnoses, and treatments were ascertained from respondents’ medical records. Gender, age, and number of IVT injections received were used as stratifications. Five-level Likert-style scales and t-tests evaluated responses and stratification comparisons. The most common diagnoses in the respondent population (n = 54; response rate = 5%) were age-related macular degeneration, macular edema, and diabetic retinopathy. Respondents had varying levels of education, income, and age. Most (83%) admitted feeling anxious prior to their first IVT injection, but 80% reported willingness to receive IVT injections indefinitely, with a preference for ophthalmologist visits every 1–3 months. Eye drops would be preferred over IVT injections by 76% of respondents, while 65% preferred oral tablets, due to several perceived negative factors of IVT injections and positive factors for eye drops. Stratified groups did not differ in responses to survey questions. RVD patients will accept IVT injections for vision preservation, but alternative delivery methods like eye drops or oral tablets would be preferred. Thus, development of eye drop and oral therapeutics for RVD treatment is further emphasized by these findings.
format	article
author	Brandon Jacobs Nicholas Palmer Trupti Shetty Helen Dimaras Amir Hajrasouliha Denis Jusufbegovic Timothy W. Corson
author_facet	Brandon Jacobs Nicholas Palmer Trupti Shetty Helen Dimaras Amir Hajrasouliha Denis Jusufbegovic Timothy W. Corson
author_sort	Brandon Jacobs
title	Patient preferences in retinal drug delivery
title_short	Patient preferences in retinal drug delivery
title_full	Patient preferences in retinal drug delivery
title_fullStr	Patient preferences in retinal drug delivery
title_full_unstemmed	Patient preferences in retinal drug delivery
title_sort	patient preferences in retinal drug delivery
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/eeb3a47168d044c68bc3bc7eb9108ec8
work_keys_str_mv	AT brandonjacobs patientpreferencesinretinaldrugdelivery AT nicholaspalmer patientpreferencesinretinaldrugdelivery AT truptishetty patientpreferencesinretinaldrugdelivery AT helendimaras patientpreferencesinretinaldrugdelivery AT amirhajrasouliha patientpreferencesinretinaldrugdelivery AT denisjusufbegovic patientpreferencesinretinaldrugdelivery AT timothywcorson patientpreferencesinretinaldrugdelivery
_version_	1718378486811328512

Patient preferences in retinal drug delivery

Ejemplares similares